$106 | SAVE $19 | Single User
$213 | SAVE $37 | Site License
$319 | SAVE $56 | Global License

Veloxis Pharmaceuticals AS - Financial and Strategic SWOT Analysis Review

Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review
[Lowest Price Guaranteed: $106]

Published by Global Data: 16 Aug 2019 | 234768 | In Stock
Related Topics: Business , Financial , Office , Pharmaceuticals

Introduction

Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.

- Corporate strategy – Analyst’s summarization of the company’s business strategy.

- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.

- Company history – Progression of key events associated with the company.

- Major products and services – A list of major products, services and brands of the company.

- Key competitors – A list of key competitors to the company.

- Key employees – A list of the key executives of the company.

- Executive biographies – A brief summary of the executives’ employment history.

- Key operational heads – A list of personnel heading key departments/functions.

- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Veloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company that identifies, develops and commercializes pharmaceutical drugs in transplantation and adjacent therapies. The company lead product is ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients. ENVARSUS is developed based on the company’s proprietary, patented drug delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company sells ENVARSUS XR to government agencies, specialty pharmacies, managed healthcare organizations, wholesalers and retail customers across the US, Europe and worldwide. Veloxis is headquartered in Copenhagen, Denmark.

Veloxis Pharmaceuticals AS Key Recent Developments

Aug 08,2019: Veloxis Pharmaceuticals announces financial results for the first six months of 2019

Jul 22,2019: Veloxis revises outlook for 2019 based on strong performance

May 06,2019: Veloxis Pharmaceuticals announces financial results for the first three months of 2019

Feb 27,2019: Veloxis Pharmaceuticals releases annual report for 2018

Jan 03,2019: Mark Hensley promoted to Chief Commercial Officer of Veloxis Pharmaceuticals

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents
for Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review

  • Table of Contents

    Table of Contents

    List of Tables

    List of Figures

    Section 1 - About the Company

    Veloxis Pharmaceuticals AS - Key Facts

    Veloxis Pharmaceuticals AS - Key Employees

    Veloxis Pharmaceuticals AS - Key Employee Biographies

    Veloxis Pharmaceuticals AS - Major Products and Services

    Veloxis Pharmaceuticals AS - History

    Veloxis Pharmaceuticals AS - Company Statement

    Veloxis Pharmaceuticals AS - Locations And Subsidiaries

    Head Office

    Other Locations & Subsidiaries

    Section 2 – Company Analysis

    Company Overview

    Veloxis Pharmaceuticals AS - Business Description

    Geographical Segment: Europe

    Performance

    Geographical Segment: Rest of the world (RoW)

    Performance

    Geographical Segment: United States

    Performance

    Veloxis Pharmaceuticals AS - Corporate Strategy

    Veloxis Pharmaceuticals AS - SWOT Analysis

    SWOT Analysis - Overview

    Veloxis Pharmaceuticals AS - Strengths

    Veloxis Pharmaceuticals AS - Weaknesses

    Veloxis Pharmaceuticals AS - Opportunities

    Veloxis Pharmaceuticals AS - Threats

    Veloxis Pharmaceuticals AS - Key Competitors

    Section 3 – Company Financial Ratios

    Financial Ratios - Capital Market Ratios

    Financial Ratios - Annual Ratios

    Performance Chart

    Financial Performance

    Financial Ratios - Interim Ratios

    Financial Ratios - Ratio Charts

    Section 4 – Company’s Lifesciences Financial Deals and Alliances

    Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

    Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

    Veloxis Pharmaceuticals AS, Recent Deals Summary

    Section 5 – Company’s Recent Developments

    Aug 08, 2019: Veloxis Pharmaceuticals announces financial results for the first six months of 2019

    Jul 22, 2019: Veloxis revises outlook for 2019 based on strong performance

    May 06, 2019: Veloxis Pharmaceuticals announces financial results for the first three months of 2019

    Feb 27, 2019: Veloxis Pharmaceuticals releases annual report for 2018

    Jan 03, 2019: Mark Hensley promoted to Chief Commercial Officer of Veloxis Pharmaceuticals

    Nov 14, 2018: Veloxis Pharmaceuticals announces financial results for the first nine months of 2018

    Oct 31, 2018: Ira Duarte promoted to chief financial officer of Veloxis Pharmaceuticals

    Sep 24, 2018: Morten Marott Steps Down as Chief Financial Officer of Veloxis Pharmaceuticals

    Aug 13, 2018: Veloxis Pharmaceuticals announces financial results for the first six months of 2018

    May 14, 2018: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018

    Section 6 – Appendix

    Methodology

    Ratio Definitions

    About GlobalData

    Contact Us

    Disclaimer

List Of Tables
in Veloxis Pharmaceuticals AS - Financial and Strategic SWOT Analysis Review

List of Tables

Veloxis Pharmaceuticals AS, Key Facts

Veloxis Pharmaceuticals AS, Key Employees

Veloxis Pharmaceuticals AS, Key Employee Biographies

Veloxis Pharmaceuticals AS, Major Products and Services

Veloxis Pharmaceuticals AS, History

Veloxis Pharmaceuticals AS, Subsidiaries

Veloxis Pharmaceuticals AS, Key Competitors

Veloxis Pharmaceuticals AS, Ratios based on current share price

Veloxis Pharmaceuticals AS, Annual Ratios

Veloxis Pharmaceuticals AS, Annual Ratios (Cont...1)

Veloxis Pharmaceuticals AS, Interim Ratios

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Veloxis Pharmaceuticals AS, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List Of Figures, Charts and Diagrams
in Veloxis Pharmaceuticals AS - Financial and Strategic SWOT Analysis Review

List of Figures

Veloxis Pharmaceuticals AS, Performance Chart (2014 - 2018)

Veloxis Pharmaceuticals AS, Ratio Charts

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

Additional Details

Publisher

Global Data

Publisher Information

Reference

234768 |

Number of Pages

45

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Veloxis Pharmaceuticals AS (VELO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryVeloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company that identifies, ...
09 Nov 2018 by Global Data USD $213 (normally
USD $251)
More Info
SAVE 15% today! Veloxis Pharmaceuticals AS (VELO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryVeloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company, which develops t...
23 Aug 2017 by Global Data USD $213 (normally
USD $251)
More Info
SAVE 15% today! Veloxis Pharmaceuticals AS (VELO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryVeloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company, which develops t...
17 May 2017 by Global Data USD $213 (normally
USD $251)
More Info
SAVE 15% today! Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review
Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review provides you an in-...
16 May 2017 by Global Data USD $106 (normally
USD $125)
More Info
SAVE 15% today! Veloxis Pharmaceuticals AS (VELO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryVeloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company, which develops t...
22 Mar 2017 by Global Data USD $213 (normally
USD $251)
More Info
SAVE 15% today! Veloxis Pharmaceuticals AS (VELO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryVeloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company, which develops t...
28 Nov 2016 by Global Data USD $213 (normally
USD $251)
More Info
SAVE 15% today! Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review
Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review provides you an in-...
21 Jun 2016 by Global Data USD $106 (normally
USD $125)
More Info
SAVE 15% today! Veloxis Pharmaceuticals AS (VELO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryVeloxis Pharmaceuticals A/S (Veloxis), formerly LifeCycle Pharma A/S, is a specialty pharmace...
10 May 2016 by Global Data USD $213 (normally
USD $251)
More Info
SAVE 15% today! Veloxis Pharmaceuticals AS (VELO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryVeloxis Pharmaceuticals A/S (Veloxis), formerly LifeCycle Pharma A/S, is a specialty pharmace...
09 Mar 2016 by Global Data USD $213 (normally
USD $251)
More Info
SAVE 15% today! Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review
Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review provides you an in-...
20 Oct 2015 by Global Data USD $106 (normally
USD $125)
More Info

This report is published by Global Data

Download Free Report Summary PDF

Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...